Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
NCT05565807
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
84
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
BIOLOGICAL:
STI-6129
Sponsor
Zhejiang ACEA Pharmaceutical Co. Ltd.